In a report published Thursday, Benchmark Company analyst James Terwilliger downgraded the rating on ICU Medical ICUI from Buy to Hold, but reiterated the $69.00 price target.
In the report, Terwilliger noted, “We are lowering our recommendation to Hold from Buy based on valuation as ICU Medical has traded close to our $69.00 price target. Our $69.00 price target represents 20 times our 2013 EPS estimate of $2.80 plus $13.00 in cash per share. We remind investors that ICU Medical has a strong balance sheet with approximately $16.00 in cash per share and no long-term debt. We believe that ICU Medical could be exploring a sale of the company, according to a Bloomberg News report.”
ICU Medical closed on Wednesday at $68.80.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in